J Pathol Transl Med.
2024 Jul;58(4):147-164. 10.4132/jptm.2023.11.01.
Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP
- Kim M
1 - Shim HS2
- Kim S3
- Lee IH4
- Kim J5
- Yoon S6
- Kim HD6
- Park I6
- Jeong JH6
- Yoo C6
- Cheon J6
- Kim IH7
- Lee J7
- Hong SH7
- Park S8
- Jung HA8
- Kim JW9
- Kim HJ10
- Cha Y11
- Lim SM12
- Kim HS12
- Lee CK12
- Kim JH13
- Chun SH14
- Yun J15
- Park SY16
- Lee HS17
- Cho YM5
- Nam SJ5
- Na K18
- Yoon SO2
- Lee A19
- Jang KT20
- Yun H3
- Lee S3
- Kim JH9
- Kim WS21
- Affiliations
-
- 1Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
- 2Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
- 3Department of Genomic Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
- 4Department of Oncology/Hematology, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Korea
- 5Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- 6Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- 7Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 8Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- 9Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
- 10Division of Oncology and Hematology, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea
- 11Division of Medical Oncology, Center for Colorectal Cancer, National Cancer Center, Goyang, Korea
- 12Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
- 13Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
- 14Division of Medical Oncology, Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 15Division of Hematology/Oncology, Department of Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea
- 16Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
- 17Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
- 18Department of Pathology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Korea
- 19Department of Hospital Pathology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 20Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- 21Department of Pathology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea
- KMID: 2557755
- DOI: http://doi.org/10.4132/jptm.2023.11.01
Abstract
- In recent years, next-generation sequencing (NGS)–based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP
- Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
- Brief History of Standardization of Korean Terminology in the Field of Pathology
- Genetic tests by next-generation sequencing in children with developmental delay and/or intellectual disability
- Utility of Next-Generation Sequencing for Deciphering Intratumor Heterogeneity in Prostate Cancer
